Hematology-OncologyKMT2A::MLLT10measurable residual disease
Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact
By MedXY|Oct 14, 2025
MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.